Non-Small Cell Lung Cancer (NSCLC) | Norton Healthcare

Indication: Non-Small Cell Lung Cancer (NSCLC)

A PHASE 2 STUDY OF BA3011 ALONE AND IN COMBINATION WITH NIVOLUMAB IN ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAD PRIOR DISEASE PROGRESSION ON A PD-1/L-1 INHIBITOR

Sub-indication: Lung Cancer

Drug Study

Principal Investigator: Adam Lye, M.D.
Norton Cancer Institute

Sponsor: BioAtla LLC

Learn more at ClinicalTrials.gov

Email for more information: Lung-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.